Vantage logo

Blueprint for disappointment

Ayvakit hits in its pivotal indolent systemic mastocytosis trial, but a dwindling effect size reignites commercial concerns.

Vantage logo

Unpacking Royalty Pharma

The serial acquirer of royalty interests is coming into its own, but the secret to its success lies in cystic fibrosis.